Grant Support

5R01 AI103960-02 (MPI) (Diamond & Barry)                                    
05/15/13 – 04/30/17                
NIH                              
HCMV Vaccine produced from BAC-MVA that Blocks Epithelial and Fibroblast Entry
The major goals are to construct an MVA expressing Human-UL128 pentamer using BAC-MVA technology, immunization of RhCMV-negative monkeys, and characterize humoral responses that inhibit CMV infection of fibroblasts and epithelial cells, with and without pp65-gB-MVA.
Role: PD/Principal Investigator (Contact)

5R01 CA077544-13 (Diamond)
05/01/12 - 11/30/17
NCI                              
Control of CMV infection post-HCT using attenuated MVA-based CMV subunit vaccine
The major goal of this continuation project is to evaluate a multi-subunit CMV vaccine in human subjects including a safety study in healthy adults and a therapeutic trial in HCT recipients.
Role: Principal Investigator

1R01CA181045-01 (Diamond)                                                           
09/03/14 – 08/31/19
NCI                                                                                          
CMVPepVax to Protect HCT Recipients from Cytomegalovirus Infection
The major goal is to conduct single and multi-center Phase 2 trials using a broad spectrum of stem cell transplant recipients to test the protective efficacy of CMVPepVax to limit CMV infection.  Impact Score = 30 (18%)
Role: Principal Investigator

1R01HL122216 (Miller)
12/1/14 - 11/30/18
NIH                  
Inducing NK cells to remember and fight cancer
Provide regular consults and provide insight into the natural history of CMV infection in transplant recipients and the role of adaptive and innate immunity to control the infection.
Role: Co-Investigator

1R01HD079918-01 (Schleiss)
08/16/15-07/31/20
NIH                  
Optimized Vaccines Against Congenital Infection and Maternal Reinfection with CMV
Supervise construction of a gpCMV pentamer vaccine in BAC-MVA. Demonstrate expression and assembly of the pentamer using in vitro immunochemical and biochemical approaches.
Role: Co-Investigator

P01 CA111412 (Miller)
04/01/16-03/31/21
NCI                    
NK cells, their receptors, transplantation and cancer therapy
Project 2: Therapeutic Potential of Adaptive NK Cells in Transplantation
Major goal: Determine the requirements for the expansion of adaptive NK cells, explore the role of STAT3 signaling in the differentiation of adaptive NK cells, evaluate the impact of CMV-induced adaptive NK cells on relapse protection and on T cell reconstitution after transplantation, and assess the in vivo anti-tumor activity of adaptive NK cells in human tumor-bearing mice.
Role: Co-Investigator

Helocyte, Inc. (Diamond)                                                
PepVax Program: Major goal is acceleration of the PepVax (IRB #13494) clinical trial
Role: Principal Investigator

Helocyte, Inc (Diamond)
Triplex Program: Major goal is acceleration of the Triplex (IRB #14295) clinical trial
Role: Principal Investigator

p53MVA Pipeline Project Award (Diamond)
01/20/14 – 02/28/17
Phase 1 study combining a p53MVA vaccine with ipilimumab and nivolumab
Major Goal: To conduct a clinical trial using a new clinical lot of vaccine in pancreatic, ovarian, and sarcoma patients.
Role: Principal Investigator

Caltech COH Collaboration (Diamond)                                    
08/01/15 – 12/31/16    
Structural analysis of soluble human cytomegalovirus (HCMV) pentamer complex-a key component of a vaccine to prevent congenital HCMV infection
The main goal for this one year proposal is to produce a soluble functional PC complex in the baculovirus expression system (BEVS) and determine the purity, homogeneity and functional activity of the PC protein by biochemical and biophysical methods.

Leo and Anne Albert Award (Manuel)
09/01/15-12/30/16
Salmonella-Based Therapy for Treatment of Kras-Dependent and Kras-Independent PDAC Tumors
The major goal of this project is to develop and test an approach utilizing a Salmonella-based technology targeting mutant Kras and bypass pathways using shRNA plasmids as a means to induce pancreatic cancer cell death.
Role: Principal Investigator

City of Hope Shared Resources (Manuel)
06/01/16-05/31/17
Combinatorial Approach Using WT1 Vaccination and PD1 Inhibition for the Treatment of AML
The major goal of this project is to test the combination of an MVA-based WT1 vaccine with prior or subsequent treatment of anti-PD1 in pre-clinical models of acute leukemia.
Role: Principal Investigator

Caltech-City of Hope Research Collaboration (Manuel)
Biomedical Research Initiative Award
08/01/16-07/31/17
Evaluating Expression Patterns of Transposable Elements in Early PanIN and Late Stage PDA
The major goal of the pilot project is to determine whether unique TE signatures exist within pancreatic intraepithelial neoplasms and pancreatic adenocarcinomas during cancer progression.
Role: Principal Investigator

K01 CA184388-02 (Ogembo)
08/05/2014-07/31/2019
National Cancer Institute (NCI)
Unmasking the roles of KSHV glycoproteins in virus entry and vaccine development
Role: Principal Investigator

Pilot Grant (Ogembo)
09/01/2014-09/31/2016
Wisconsin National Primate Research Center
Towards KSHV VLP based vaccine development
Role: Principal Investigator

Pilot Grants (Ogembo)
06/01/2016-05/30/2017
City of Hope Pilot Project Awards Supporting Innovative Health Equity Research
Characterization of High-risk HPV polymorphisms in ICC cases from Hispanics women
Role: Principal Investigator

Pilot Grants (Ogembo)
06/01/2016-05/30/2017
Toni Stephenson Lymphoma Center Pilot Grant Program
Identification of targets for developing Epstein-Barr virus vaccines
Role: Principal Investigator

St. Baldrick’s Foundation (Ogembo)
10/01/2016-09/30/2018
A novel immunotherapeutic candidate vaccine against Kaposi sarcoma
The overall goal of the project is to develop a polyvalent vaccine against Kaposi sarcoma the most common malignancies among HIV/AIDS patients (submitted March 2016).
Role: Co-Principal Investigator